The control rate of advanced pancreatic cancer is 77%! Keytruda triple therapy phase 2 results positive

Recently, biolinerx company announced the results of phase 2A clinical trials of bl-8040 and PD-1 antibody keytruda developed by the company, as well as the combination of chemotherapy in the treatment of metastatic pancreatic cancer patients at the ESMO IO conference Bl-8040 is a peptide antagonist targeting CXCR4 The results showed that the combined therapy showed a promising anticancer activity in patients with metastatic pancreatic cancer Pancreatic cancer, also known as the "king of cancer", is known for its rapid progress and high mortality Especially when patients develop resistance to first-line therapy, second-line treatment options are very limited Because pancreatic cancer is a "cold" tumor, even if we get a lot of immunosuppressive checkpoint inhibitors in many types of cancer, the effect of single drug in the treatment of pancreatic cancer is not satisfactory Bl-8040 is a "best in class" CXCR4 reverse agonist CXCR4 is a highly expressed trend factor receptor in a variety of human cancers, and its high expression is associated with poor prognosis Preclinical and clinical studies have shown that by inhibiting the function of CXCR4, bl-8040 can affect immune cell transport, affect tumor infiltration of T cells, and reduce immunosuppressive cells in tumor microenvironment, thus turning "cold" tumors into "hot" Action mechanism of bl-8040 (picture source: reference [2]) In the phase 2A clinical trial named Comat / keynote-202, as of December 5 this year, a total of 36 patients participated in the clinical trial These patients had stage IV metastatic pancreatic cancer, and the disease continued to progress after first-line chemotherapy The trial data showed that of the 22 patients who could receive efficacy evaluation, 7 achieved partial remission (PR), 10 achieved stable disease (SD), the total remission rate (ORR) was 32%, and the disease control rate (DCR) was 77% This value is better than the current second-line standard chemotherapy (ORR 17%, DCR 52%) In the course of treatment, 5 patients with stable disease status changed to partial remission as the treatment continued, showing the lasting effect of this combination Of the seven patients who received partial remission, five were still receiving treatment for a maximum of 330 days Source: reference [2] "Metastatic pancreatic cancer has a very poor response to chemotherapy, and immunotherapy as a single drug has little effect," said Dr Manuel Hidalgo of Weill Cornell Medical, who led the study I'm looking forward to seeing patient survival data in the middle of next year " reference material: [1] BioLineRx Announces Updated Phase 2a Data From Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Cancer Retrieved December 13, 2019, from https:// [2] A Multi-Center Phase 2a Trial to Assess the Safety and Efficacy of BL-8040 (a CXCR4 inhibitor) in Combination with Pembrolizumab and Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma (PDAC) Retrieved December 13, 2019, from https://ir.biolinerx.com/static-files/19533d3c-9dfe-47f0-8300-bb1d0af97091 A kind of